- Definition

Represents the maximum royalties to be received by the entity from the other party in a collaborative arrangement, expressed as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	thrx_AnnualRoyaltiesPercentageOfNetSales
Namespace Prefix:	thrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum amount eligible to receive under the collaborative arrangement through achieving development milestones.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementDevelopmentMilestonesReceive
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount of potential future payments that may be received under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementMaximumPotentialFuturePayments
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount eligible to receive under the collaborative arrangement for near-term licensing fees.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementNearTermLicensingFeesReceive
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount eligible to receive under the collaborative arrangement through achieving net sales milestones.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementNetSalesMilestonesReceive
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the number of separate development and commercialization agreements with another entity.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementNumberOfSeparateDevelopmentAndCommercializationAgreements
Namespace Prefix:	thrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the option fee funding amount that the entity is entitled to receive if exercised under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementOptionFeeFundingAmount
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount of potential development, regulatory and sales milestone payments that the entity is entitled to receive under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementPotentialDevelopmentRegulatoryAndSalesMilestoneMaximumPaymentPotential
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the cumulative amount of upfront fees to be received under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementUpfrontFeesToBeReceived
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Subsequent Events (Details) (Subsequent event, USD $) In Millions, unless otherwise specified		0 Months Ended
	Oct. 01, 2012 Development and commercialization Alfa Wassermann Velusetrag (or TD-5108)	Oct. 03, 2012 Development and commercialization Alfa Wassermann Velusetrag (or TD-5108) Maximum	Oct. 19, 2012 Development and commercialization R-Pharm CJSC item	Oct. 19, 2012 Development and commercialization R-Pharm CJSC TD-1792	Oct. 19, 2012 Development and commercialization R-Pharm CJSC Telavancin	Oct. 15, 2012 Discover, develop, and commercialize Merck Novel small molecule therapeutics
Information related to subsequent events
Option fee funding amount	$ 10.0
Maximum potential development, regulatory and sales milestone payments eligible to receive	53.5
Maximum royalties eligible to receive expressed as a percentage of net sales		20.00%		15.00%	25.00%
Upfront payment to be received						5.0
Potential future payments to be received						148.0
Number of separate development and commercialization agreements			2
Maximum amount eligible to receive through near-term licensing fees			2.0
Maximum amount eligible to receive by achieving future development milestones			4.0
Maximum amount eligible to receive by achieving future sales milestones			$ 6.0